Beta společnosti Beam Therapeutics
Jaká je hodnota metriky Beta společnosti Beam Therapeutics?
Hodnota metriky Beta společnosti Beam Therapeutics Inc. je 1.82
Jaká je definice metriky Beta?
BETA koeficient vyjadřuje, zda je akcie více či méně volatilní než trh jako celek. Beta menší než 1 znamená, že akcie jsou méně volatilní než trh, zatímco beta větší než 1 znamená, že akcie jsou volatilnější. Volatilita se měří pomocí fluktuace ceny akcie.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Beam Therapeutics
Čemu se věnuje společnost Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Firmy s metrikou beta podobnou společnosti Beam Therapeutics
- Hodnota metriky Beta společnosti Capita Plc je 1.82
- Hodnota metriky Beta společnosti Orocobre je 1.82
- Hodnota metriky Beta společnosti First Plc je 1.82
- Hodnota metriky Beta společnosti Cerevel Therapeutics je 1.82
- Hodnota metriky Beta společnosti Shenzhen Transsion Co je 1.82
- Hodnota metriky Beta společnosti Incap Oyj je 1.82
- Hodnota metriky Beta společnosti Beam Therapeutics je 1.82
- Hodnota metriky Beta společnosti Eledon Pharmaceuticals je 1.82
- Hodnota metriky Beta společnosti Beijing Enterprises Clean je 1.82
- Hodnota metriky Beta společnosti Carpentaria Resources je 1.82
- Hodnota metriky Beta společnosti Reliance Naval and Engineering je 1.82
- Hodnota metriky Beta společnosti Medicamen Biotech je 1.82
- Hodnota metriky Beta společnosti Guyana Goldstrike je 1.82